Literature DB >> 24841541

Primary and prosthetic repair of acquired chest wall hernias: a 20-year experience.

Christopher W Seder1, Mark S Allen1, Francis C Nichols1, Dennis A Wigle1, K Robert Shen1, Claude Deschamps1, Stephen D Cassivi2.   

Abstract

BACKGROUND: Chest wall herniation has been described after thoracotomy, trauma, and violent coughing episodes. Few studies have examined risk factors associated with chest wall herniation or predictors of complications after surgical repair.
METHODS: A divisional database identified all patients who underwent chest wall herniorrhaphy between 1992 and 2011. Data were collected on patient age, sex, body mass index (BMI), cause and location of hernia, comorbidities, duration and technique of herniorrhaphy, postoperative complications, and hospital length of stay. Risk factors for chest wall herniation were then examined, and primary repair was compared with prosthetic repair for differences in postoperative morbidity.
RESULTS: Twenty-seven consecutive patients underwent chest wall herniorrhaphy. Hernias most commonly occurred on the right side, in the fifth intercostal space, contained lung, and were chronic in nature. Pain was the presenting symptom in all but 4 patients. The most frequently observed comorbidities were obesity, chronic obstructive pulmonary disease (COPD), oral steroid use, and diabetes mellitus. Primary repair was performed in 18 patients and mesh repair in 9 patients, with a median operative time of 116 minutes. Excluding the 4 acute hernias repaired during the same admission as the initial thoracotomy, postoperative complications occurred in 22% of patients who underwent prosthetic repair and 42% of patients who underwent primary repair (p=0.4). Median hospital stay did not differ between herniorrhaphy techniques.
CONCLUSIONS: Previous thoracotomy, obesity, COPD, steroid use, and diabetes mellitus are common in patients in whom chest wall hernias develop. Prosthetic herniorrhaphy is not associated with an increased risk of postoperative complications relative to primary repair.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24841541     DOI: 10.1016/j.athoracsur.2014.03.021

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Traumatic thoracoabdominal hernia repair using a novel chest-wall reconstruction technique: a case report.

Authors:  M Aladaileh; A O'Driscoll-Collins; F O'Keeffe; J B Conneely; K Redmond
Journal:  Ann R Coll Surg Engl       Date:  2019-09-11       Impact factor: 1.891

2.  Resection of a bony tumour of the chest wall with direct reconstruction using a sandwich technique: a standard technique for closure of large chest wall defects.

Authors:  Karlijn Hummelink; Michiel A IJsseldijk; Anne Marie Bosch; Richard P G Ten Broek; K C Anthon van Engelenburg
Journal:  J Surg Case Rep       Date:  2015-04-15

3.  Use of porcine acellular dermal matrix to repair lung Hernia after minithoracotomy: A case report with 6-Year follow-up.

Authors:  Antonio Stanizzi; Matteo Torresetti; Michele Salati; Giovanni Di Benedetto
Journal:  JPRAS Open       Date:  2021-02-07

4.  Inverted intercostal hernia of elastofibroma dorsi mimicking well-differentiated liposarcoma in the chest wall.

Authors:  Rika Yoshida; Takeshi Yoshizako; Kazuya Okamura; Shinji Ando; Megumi Nakamura; Noriyoshi Ishikawa; Hajime Kitagaki
Journal:  Acta Radiol Open       Date:  2022-03-30

5.  The Use of Acellular Dermal Matrix (Integra Single Layer) for the Correction of Malformative Chest Wall Deformities: First Case Series Reported.

Authors:  Carlos Delgado-Miguel; Miriam Miguel-Ferrero; Antonio Muñoz-Serrano; Mercedes Díaz; Juan Carlos López-Gutiérrez; Carlos De la Torre
Journal:  Surg J (N Y)       Date:  2022-08-16

6.  Giant spontaneous herniation of the post-pneumonectomy cavity.

Authors:  Alessandro Tamburrini; Adnan Raza; Aiman Alzetani
Journal:  J Surg Case Rep       Date:  2017-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.